Comparative Pharmacology
Head-to-head clinical analysis: OXTRIPHYLLINE versus SOMOPHYLLIN CRT.
Head-to-head clinical analysis: OXTRIPHYLLINE versus SOMOPHYLLIN CRT.
OXTRIPHYLLINE vs SOMOPHYLLIN-CRT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular cAMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/mL.
None Documented
None Documented
Clinical Note
moderateOxtriphylline + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Acemetacin
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Oxtriphylline."
Clinical Note
moderateOxtriphylline + Clotrimazole
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Category C
Category C
Bronchodilator
Bronchodilator
"The metabolism of Clotrimazole can be decreased when combined with Oxtriphylline."